


World Journal of *Stem Cells*

World J Stem Cells 2011 May 26; 3(5): 43-52





Editorial Board

2009-2013

The *World Journal of Stem Cells* Editorial Board consists of 284 members, representing a team of worldwide experts in stem cells research. They are from 28 countries, including Australia (5), Austria (1), Belgium (3), Brazil (2), Canada (7), China (19), Czech Republic (2), Denmark (4), Finland (3), France (5), Germany (14), Hungary (3), India (3), Iran (1), Israel (4), Italy (13), Japan (18), Netherlands (4), Norway (2), Singapore (10), South Korea (15), Spain (6), Sweden (2), Switzerland (3), Turkey (2), United Arab Emirates (1), United Kingdom (15), and United States (117).

PRESIDENT AND EDITOR-IN-CHIEF

Lian-Sheng Ma, *Beijing*

STRATEGY ASSOCIATE EDITORS-IN-CHIEF

Philippe Bourin, *Toulouse*
Andras Dinnyes, *Godollo*
Umberto Galderisi, *Napoli*
Mikhail G Kolonin, *Houston*
Balazs Sarkadi, *Budapest*

GUEST EDITORIAL BOARD MEMBERS

Ing-Ming Chiu, *Miaoli*
Chie-Pein Chen, *Taipei*
Ju Jyh-Cherng, *Taichung*
Hossein Hosseinkhani, *Taipei*
Steven Shoen-Lung Li, *Kasohsiung*
Tzu-Hao Wang, *Tao-Yuan*

MEMBERS OF THE EDITORIAL BOARD



Australia

Jeremy M Crook, *Melbourne*
Alice Pébay, *Victoria*
Kuldip S Sidhu, *Sydney*
Ernst Wolvetang, *Brisbane*
Xin-Fu Zhou, *Adelaide*



Austria

Ludwig Aigner, *Salzburg*



Belgium

Yves Beguin, *Liege*

Mieke Geens, *Brussels*
Najimi Mustapha, *Brussels*



Brazil

Niels Olsen Saraiva Câmara, *São Paulo*
Naiara Zoccal Saraiva, *Jaboticabal*



Canada

Borhane Annabi, *Montreal*
Rosario Isasi, *Quebec*
Xiao-Yan Jiang, *Vancouver*
Seung U Kim, *Vancouver*
Ren-Ke Li, *Toronto*
Jeffrey A Medin, *Toronto*
Kursad Turksen, *Ottawa*



China

Xiu-Wu Bian, *Chongqing*
Yong Dai, *Shenzhen*
Zhong-Chao Han, *Tianjin*
Zhang Hao, *Beijing*
Anskar YH Leung, *Hong Kong*
Gang Li, *Hong Kong*
Gui-Rong Li, *Hong Kong*
Kai-Yan Liu, *Beijing*
Yi-Jia Lou, *Hangzhou*
Xue-Tao Pei, *Beijing*
Jing-He Tan, *Tan-An*
Jin-Fu Wang, *Hangzhou*
Yun-Hai Zhang, *Hefei*



Czech Republic

Petr Dvorak, *Brno*
Jaroslav Mokry, *Hradec Kralove*



Denmark

Basem M Abdallah, *Odense*
Poul Maddox-Hyttel, *Frederiksberg*
Lin Lin, *Tjele*
Soren Paludan Sheikh, *Odense*



Finland

Jukka Partanen, *Helsinki*
Petri Salven, *Helsinki*
Heli Skottman, *Tampere*



France

Alain Chapel, *Paris*
Gwendal Lazennec, *Montpellier*
Muriel Perron, *Paris*
Xavier Thomas, *Lyon*



Germany

James Adjaye, *Berlin*
Christian Buske, *Ulm*
Denis Corbeil, *Dresden*
Frank Edenhofer, *Bonn*
Ursula Margarethe Gehling, *Langen*
Eric Gottwald, *Eggenstein-Leopoldshafen*
Jorg Kleeff, *Munich*
Gesine Kögler, *Düsseldorf*
Nan Ma, *Rostock*
Ulrich Martin, *Hannover*
Heinrich Sauer, *Giessen*
Richard Schäfer, *Tübingen*
Sonja Schrepfer, *Hamburg*
Wolfgang Wagner, *Aachen*

**Hungary**

Ferenc Uher, *Budapest*

**India**

Gurudutta U Gangenahalli, *Delhi*
Asok Mukhopadhyay, *New Delhi*
Anjali Suhas Shiras, *Maharashtra*

**Iran**

Masoud Soleimani, *Tehran*

**Israel**

Zeev Blumenfeld, *Haifa*
Rachel Sarig, *Rehovot*
Avichai Shimoni, *Tel-Hashomer*
Shimon Slavin, *Tel Aviv*

**Italy**

Carlo Alberto Beltrami, *Udine*
Clotilde Castaldo, *Naples*
Carmelo Carlo-Stella, *Milano*
Massimo Dominici, *Modena*
Stefania Filos, *Naples*
Angela Gritti, *Milano*
Roberta Morosetti, *Rome*
Felicita Pedata, *Florence*
Anna Chiara Piscaglia, *Rome*
Stefano Pluchino, *Milan*
Caterina AM La Porta, *Milan*
Domenico Ribatti, *Bari*

**Japan**

Tomoki Aoyama, *Kyoto*
Susumu Ikehara, *Osaka*
Taro Matsumoto, *Tokyo*
Yuko Miyagoe-Suzuki, *Tokyo*
Hiroyuki Miyoshi, *Tsukuba*
Takashi Nagasawa, *Kyoto*
Tetsuhiro Niidome, *Kyoto*
Toshio Nikaido, *Toyama*
Kohzo Nakayama, *Nagano*
Tsukasa Ohmori, *Tochigi*
Caterina AM La Porta, *Milan*
Kumiko Saeki, *Tokyo*
Kazunobu Sawamoto, *Aichi*
Mikiko C Siomi, *Tokyo*
Yoshiaki Sonoda, *Osaka*
Takashi Tada, *Kyoto*
Kotaro Yoshimura, *Tokyo*
Louis Yuge, *Hiroshima*

**Netherlands**

Dirk Gijsbert de Rooij, *Amsterdam*

Christine Mummery, *Leiden*
Frank JT Staal, *Leiden*
Marten Piet Smidt, *Utrecht*

**Norway**

Brynjar Foss, *Stavanger*
Berit Bølge Tysnes, *Bergen*

**Singapore**

Yu Cai, *Research Link*
Tong Cao, *Singapore*
Jerry Chan, *Singapore*
Gavin Stewart Dawe, *Medical Drive*
Chan Kwok-Keung Ken, *Singapore*
Chan Woon Khiong, *Singapore*
Steve KW Oh, *Singapore*
Seeram Ramakrishna, *Singapore*
Herbert Schwarz, *Singapore*
Shu Wang, *Biopolis Way*

**South Korea**

Jong Wook Chang, *Seoul*
Chong-Su Cho, *Seoul*
Ssang-Goo Cho, *Seoul*
Ho Jae Han, *Gwangju*
Ki-Chul Hwang, *Seoul*
Kyung-Sun Kang, *Seoul*
Haekwon Kim, *Seoul*
Hoeon Kim, *Daejeon*
Mee Kum Kim, *Seoul*
Yoon Jun Kim, *Seoul*
Soo-Hong Lee, *Seoul*
Dae-Sik Lim, *Daejeon*
Byung Soon Park, *Seoul*
Sun U Song, *Incheon*
Seung Kwon You, *Seoul*

**Spain**

Fernando Cobo, *Granada*
Sabrina C Desbordes, *Barcelona*
Marta Muñoz Llamosas, *España*
Maria P De Miguel, *Madrid*
María Dolores Miñana, *Valencia*
Felipe Prosper, *Navarra*

**Sweden**

M Quamrul Islam, *Linköping*
Stefan Karlsson, *Lund*

**Switzerland**

Thomas Daikeler, *Basel*
Sabrina Mattoli, *Basel*
Arnaud Scherberich, *Basel*

**Turkey**

Alp CAN, *Ankara*
Berna Arda, *Ankara*

**United Arab Emirates**

Sherif M Karam, *Al-Ain*

**United Kingdom**

Dominique Bonnet, *London*
Kristin Mary Braun, *London*
Wei Cui, *London*
David C Hay, *Edinburgh*
Wael Kafienah, *Bristol*
Francis L Martin, *Lancaster*
Mike Modo, *London*
Donald Palmer, *London*
Dame Julia Polak, *London*
James Alexander Ross, *Edinburgh*
Alastair James Sloan, *Cardiff*
Virginie Sottile, *Nottingham*
Hong Wan, *London*
He-Ping Xu, *Aberdeen*
Rike Zietlow, *Cardiff*

**United States**

Gregor Barr Adams, *Los Angeles*
Kinji Asahina, *Los Angeles*
Craig S Atwood, *Madison*
Debabrata Banerjee, *New Brunswick*
Aline M Betancourt, *New Orleans*
Surinder Kumar Batra, *Omaha*
Bruce Alan Bunnell, *New Orleans*
Jason A Burdick, *Philadelphia*
Anthony WS Chan, *Atlanta*
Rebecca J Chan, *Indianapolis*
G Rasul Chaudhry, *Rochester*
Jonathan Donald Chesnut, *Carlsbad*
Herman S Cheung, *Coral Gables*
Kent W Christopherson II, *Chicago*
David Wade Clapp, *Indianapolis*
Rubin Clinton, *New York*
Claudius Conrad, *Boston*
Charles Samuel Cox, *Houston*
Marcos de Lima, *Houston*
Douglas C Dean, *Louisville*
Goberdhan Dimri, *Evanston*
David Dingli, *Rochester*
Fu-Liang Du, *Vernon*
Todd Evans, *New York*
Toshihiko Ezashi, *Columbia*
Vincent Falanga, *Alternate*
Ira J Fox, *Pittsburgh*
Markus Frank, *Boston*
Sanga Gehmert, *Houston*
Yong-Jian Geng, *Houston*
Joseph C Glorioso, *Pittsburgh*
Kristbjorn Orri Gudmundsson, *Frederick*
Yan-Lin Guo, *Hattiesburg*
Tong-Chuan He, *Chicago*
Lorraine Iacovitti, *Philadelphia*
Kunlin Jin, *Novato*

Michael R King, *Ithaca*
 Uma Lakshmiopathy, *Carlsbad*
 Hillard Michael Lazarus, *Shaker Heights*
 Techung Lee, *Buffalo*
 Robert C Miller, *Rochester*
 Tao-Sheng Li, *Los Angeles*
 Xiao-Nan Li, *Houston*
 Ching-Shwun Lin, *San Francisco*
 P Charles Lin, *Nashville*
 Su-Ling Liu, *Ann Arbor*
 Aurelio Lorico, *Las Vegas*
 Jean-Pierre Louboutin, *Philadelphia*
 Bing-Wei Lu, *Stanford*
 Qing Richard Lu, *Dallas*
 Nadya L Lumelsky, *Bethesda*
 Hong-Bo R Luo, *Boston*
 Hinh Ly, *Atlanta*
 Teng Ma, *Tallahassee*
 Kenneth Maiese, *Detroit*
 Robert L Mauck, *Philadelphia*
 Glenn Edwards McGee, *New York*
 Murielle Mimeault, *Omaha*
 Guo-Li Ming, *Baltimore*
 Masato Nakafuku, *Cincinnati*
 Christopher Niyibizi, *Hershey*
 Seh-Hoon Oh, *Gainesville*
 Frank Pajonk, *Los Angeles*

Gregory M Pastores, *New York*
 Derek A Persons, *Memphis*
 Donald G Phinney, *Florida*
 Donald George Phinney, *New Orleans*
 Dimitris G Placantonakis, *New York*
 George E Plopper, *Troy*
 Derek Radisky, *Jacksonville*
 Murugan Ramalingam, *Gaithersburg*
 Pranela Rameshwar, *Newark*
 Jeremy N Rich, *Cleveland*
 Angie Rizzino, *Omaha*
 Paul Ronald Sanberg, *Tampa*
 Gerald Phillip Schatten, *Pittsburgh*
 Ashok Kumar Shetty, *Durham*
 Igor I Slukvin, *Madison*
 Shay Soker, *Winston-Salem*
 Hong-Jun Song, *Baltimore*
 Kenichi Tamama, *Columbus*
 Dean G Tang, *Smithville*
 Hugh S Taylor, *New Haven*
 Jonathan L Tilly, *Boston*
 Jakub Tolar, *Minneapolis*
 Deryl Troyer, *Manhattan*
 Scheffer Chuei-Goong Tseng, *Miami*
 Lyuba Varticovski, *Bethesda*
 Tandis Vazin, *Berkeley*
 Kent E Vrana, *Hershey*

Lyuba Varticovski, *Bethesda*
 Qi Wan, *Reno*
 Charles Wang, *Los Angeles*
 Guo-Shun Wang, *New Orleans*
 Zack Z Wang, *Scarborough*
 David Warburton, *Los Angeles*
 Li-Na Wei, *Jackson Hall*
 Andre Van Wijnen, *Worcester*
 Marc Adrian Williams, *Rochester*
 Joseph C Wu, *Stanford*
 Li-Zi Wu, *Gainesville*
 Sean M Wu, *Boston*
 Yan Xu, *Pittsburgh*
 Jun Yan, *Louisville*
 Jing Yang, *Orange*
 Li-Jun Yang, *Florida*
 Phillip Chung-Ming Yang, *Stanford*
 Pampee Paul Young, *Nashville*
 Hong Yu, *Miami*
 Seong-Woon Yu, *East Lansing*
 Xian-Min Zeng, *Novato*
 Bao-Hong Zhang, *Greenville*
 Ying Zhang, *Baltimore*
 Xue-Sheng Zheng, *Massachusetts*
 X Long Zheng, *Philadelphia*
 John F Zhong, *Los Angeles*



ORIGINAL ARTICLE

43

Preclinical transplantation and safety of HS/PCs expanded from human umbilical cord blood

Guo CJ, Gao Y, Hou D, Shi DY, Tong XM, Shen D, Xi YM, Wang JF

Contents

World Journal of Stem Cells
Volume 3 Number 5 May 26, 2011

ACKNOWLEDGMENTS I Acknowledgments to reviewers of *World Journal of Stem Cells*

APPENDIX I Meetings

I-V Instructions to authors

ABOUT COVER Guo CJ, Gao Y, Hou D, Shi DY, Tong XM, Shen D, Xi YM, Wang JF. Preclinical transplantation and safety of HS/PCs expanded from human umbilical cord blood.
World J Stem Cells 2011; 3(5): 43-52
<http://www.wjgnet.com/1948-0210/full/v3/i5/43.htm>

AIM AND SCOPE *World Journal of Stem Cells* (*World J Stem Cells*, *WJSC*, online ISSN 1948-0210, DOI: 10.4252), is a Monthly open-access peer-reviewed journal supported by an editorial board consisting of 284 experts in stem cell research from 28 countries.
The major task of *WJSC* is to rapidly report original articles and comprehensive reviews on basic laboratory investigations of stem cells and their application in clinical care and treatment of patients. *WJSC* is designed to cover all aspects of stem cells, including embryonic stem cells, neural stem cells, hematopoietic stem cells, mesenchymal stem cells, tissue-specific stem cells, cancer stem cells, the stem cell niche, stem cell genomics and proteomics, and translational and clinical research. In a word, papers published in *WJSC* will cover the biology, culture, and differentiation of stem cells from all stages of development from germ cell to embryo and adult.

FLYLEAF I-III Editorial Board

EDITORS FOR THIS ISSUE

Responsible Assistant Editor: *Le Zhang*
Responsible Electronic Editor: *Jin-Lei Wang*
Proofing Editor-in-Chief: *Lian-Sheng Ma*

Responsible Science Editor: *Jin-Lei Wang*
Proofing Editorial Office Director: *Jin-Lei Wang*

NAME OF JOURNAL
World Journal of Stem Cells

LAUNCH DATE
December 31, 2009

SPONSOR
Beijing Baishideng BioMed Scientific Co., Ltd.,
Room 903, Building D, Ocean International Center,
No. 62 Dongsihuan Zhonglu, Chaoyang District,
Beijing 100025, China
Telephone: +86-10-8538-1892
Fax: +86-10-8538-1893
E-mail: baishideng@wjgnet.com
<http://www.wjgnet.com>

EDITING
Editorial Board of *World Journal of Stem Cells*,
Room 903, Building D, Ocean International Center,
No. 62 Dongsihuan Zhonglu, Chaoyang District,
Beijing 100025, China
Telephone: +86-10-8538-1891
Fax: +86-10-8538-1893
E-mail: wjse@wjgnet.com
<http://www.wjgnet.com>

PUBLISHING
Baishideng Publishing Group Co., Limited,
Room 1701, 17/F, Henan Bulding,
No.90 Jaffe Road, Wanchai,
Hong Kong, China

Fax: +852-3115-8812
Telephone: +852-5804-2046
E-mail: baishideng@wjgnet.com
<http://www.wjgnet.com>

SUBSCRIPTION
Beijing Baishideng BioMed Scientific Co., Ltd.,
Room 903, Building D, Ocean International Center,
No. 62 Dongsihuan Zhonglu, Chaoyang District,
Beijing 100025, China
Telephone: +86-10-8538-1892
Fax: +86-10-8538-1893
E-mail: baishideng@wjgnet.com
<http://www.wjgnet.com>

PUBLICATION DATE
May 26, 2011

ISSN
ISSN 1948-0210 (online)

PRESIDENT AND EDITOR-IN-CHIEF
Lian-Sheng Ma, Beijing

STRATEGY ASSOCIATE EDITORS-IN-CHIEF
Philippe Bourin, Toulouse
Andras Dinnyes, Godollo
Umberto Galderisi, Napoli
Mikhail G Kolonin, Houston
Balazs Sarkadi, Budapest

EDITORIAL OFFICE
Jin-Lei Wang, Director
World Journal of Stem Cells
Room 903, Building D, Ocean International Center,
No. 62 Dongsihuan Zhonglu, Chaoyang District,
Beijing 100025, China
Telephone: +86-10-8538-1891
Fax: +86-10-8538-1893
E-mail: wjse@wjgnet.com
<http://www.wjgnet.com>

COPYRIGHT
© 2011 Baishideng. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

SPECIAL STATEMENT
All articles published in this journal represent the viewpoints of the authors except where indicated otherwise.

INSTRUCTIONS TO AUTHORS
Full instructions are available online at http://www.wjgnet.com/1948-0210/g_info_20100313165700.htm.

ONLINE SUBMISSION
<http://www.wjgnet.com/1948-0210office>

Preclinical transplantation and safety of HS/PCs expanded from human umbilical cord blood

Chun-Juan Guo, Ying Gao, Di Hou, Dong-Yan Shi, Xiang-Min Tong, Dan Shen, Yong-Mei Xi, Jin-Fu Wang

Chun-Juan Guo, Di Hou, Dong-Yan Shi, Yong-Mei Xi, Jin-Fu Wang, College of Life Sciences, Zhejiang University, Hangzhou 310058, Zhejiang Province, China

Ying Gao, The Second People's Hospital of Hangzhou, Hangzhou 310015, Zhejiang Province, China

Xiang-Min Tong, Dan Shen, The First Auxiliary Hospital of Zhejiang University, Hangzhou 310003, Zhejiang Province, China

Author contributions: Guo CJ participated in the experimental design, HS/PC expansion and analysis, determination of contamination in HS/PC product, interpretation of the data and was the primary author of the manuscript; Gao Y collected human umbilical cord blood and isolated hematopoietic stem cells, and performed the engraftment assay of HS/PC products in NOD/SCID mice; Hou D conceived the experiment, performed the culture of BM-MSCs; Shi DY detected the bacterial endotoxin concentration and stem cell factor; Tong XM collected human BM; Shen D isolated MSCs from BM; Xi YM participated in manuscript preparation; Wang JF supervised the study design, execution, analysis, and approved the final version.

Supported by Scientific Foundation of Zhejiang (2009C13020) and National Natural Science Foundation of China, No. 30971460

Correspondence to: Jin-Fu Wang, Professor, Institute of Cell Biology and Genetics, College of Life Sciences, Zijingang Campus, Zhejiang University, Hangzhou 310058, Zhejiang Province, China. wjfu@zju.edu.cn

Telephone: +86-571-88206592 Fax: +86-571-85128776

Received: August 10, 2010 Revised: January 5, 2011

Accepted: January 12, 2011

Published online: May 26, 2011

Abstract

AIM: To expand hematopoietic/progenitor stem cells (HS/PCs) from umbilical cord blood (UCB) and prepare the HS/PC product, and analyze preclinical transplantation and safety of HS/PC product.

METHODS: Human bone marrow-derived mesenchymal stem cells (MSCs) were used as feeder cells to expand HS/PCs from UCB in a serum-free culture system. The proliferation potential of HS/PCs was analyzed. The expanded HS/PCs were suspended in the L-15 medium to

prepare the HS/PC product. The contamination of bacteria, fungi and mycoplasmas, the infection of exogenous virus, the concentration of bacterial endotoxin, and the SCF residual in HS/PC product were determined. Finally, cells from the HS/PC product with or without bone marrow-derived mesenchymal stem cells (BM-MSCs) were transplanted into the irradiated NOD/SCID mice to determine the *in vivo* engraftment potential.

RESULTS: After co-culture for 10 d, the total nuclear cells (TNCs) increased 125-fold, and CD34⁺ cells increased 43-fold. The granulocyte-macrophage colony-forming cells (GM-CFCs) and erythroid colony-forming cells (E-CFCs) increased 3.3- and 4.7-fold respectively. The expanded cells were collected and prepared as the expanded product of HS/PCs by re-suspending cells in L-15 medium. For preclinical safety, the HS/PC product was analysed for contamination by bacteria, fungi and mycoplasmas, the bacterial endotoxin concentration and the SCF content. The results showed that the HS/PC product contained no bacteria, fungi or mycoplasmas. The bacterial endotoxin concentration was less than the detection limit of 6 EU/mL, and residual SCF was 75 pg/mL. Based on clinical safety, the HS/PC product was qualified for clinical transplantation. Finally, the HS/PC product was transplanted the irradiated mice where it resulted in rapid engraftment of hematopoietic cells.

CONCLUSION: HSPC product prepared from UCB in the serum-free culture system with hMSCs as feeder cells should be clinically safe and effective for clinical transplantation.

© 2011 Baishideng. All rights reserved.

Key words: Hematopoietic stem cells; *Ex vivo* expansion; Preclinical safeties; Transplantation

Peer reviewer: Kristbjorn Orri Gudmundsson, PhD, Laboratory of Cancer Prevention, Hematopoiesis and Stem Cell Biology Section, 1050 Boyles Street, Building 560, Room 12-03, NCI-Frederick, Frederick, MD 21702-1201, United States

Guo CJ, Gao Y, Hou D, Shi DY, Tong XM, Shen D, Xi YM, Wang JF. Preclinical transplantation and safety of HS/PCs expanded from human umbilical cord blood. *World J Stem Cells* 2011; 3(5): 43-52 Available from: URL: <http://www.wjgnet.com/1948-0210/full/v3/i5/43.htm> DOI: <http://dx.doi.org/10.4252/wjsc.v3.i5.43>

INTRODUCTION

Umbilical cord blood transplantation (UCBT) has been used in treatment of hematologic malignancies, aplastic anemia, hemoglobinopathies, and severe combined immunodeficiency^[1]. Compared with bone marrow and peripheral blood, umbilical cord blood (UCB) has the advantage of convenient collection, immature cellular immunity and no strict matching requirement in transplantation^[2]. Thus, hematopoietic/progenitor stem cells (HS/PCs) from UCB have potential clinical value. However, the HS/PCs in a stock of UCB are low in quantity, limiting their clinical application. Therefore, HS/PCs from UCB should be *ex vivo* expanded to meet the needs for clinical transplantation. *In vivo*, mesenchymal stem cell (MSCs) in bone marrow supply an appropriate scaffold for hematopoiesis and a complex network of cytokines, adhesion molecules, and extracellular matrix proteins that regulate survival, proliferation, growth and differentiation of HS/PCs. Bone marrow-derived mesenchymal stem cells (BM-MSCs) can be used as a feeder layer to support the *ex vivo* proliferation of HS/PCs. In co-culture systems, BM-MSCs are generally considered to provide signal transduction to promote the expansion of HS/PCs through two major mechanisms. First, BM-MSCs secrete various soluble factors, such as growth factors and cytokines that stimulate the proliferation and differentiation of HS/PCs, and make the niche an appropriate environment for the proliferation and maintenance of HS/PCs. Secondly, co-culture with BM-MSCs provides the direct cell-cell contact, which plays an important role in HS/PC proliferation and differentiation. Previous studies demonstrated that co-culture with BM-MSCs resulted in the increase of *ex vivo* proliferation, the regulation of differentiation, the decrease of apoptosis^[3-7], and the decrease of allostimulatory capacity of HS/PCs in transplantation^[8]. Culture of CD34⁺ cells culture with microencapsulated stromal cells effectively stimulated the total cell population and maintenance of primitive progenitor cells. The transplantation of their progeny was able to shorten the time to engraftment by bridging the pancytopenic period and support functional hematopoietic repopulation^[9,10].

Great attention should be paid to the preclinical safety of any *ex vivo* expanded cell product before clinical transplantation. It was reported that the static amplification of BM-MSCs is prone to contamination^[11]. Any carelessness during culture may result in the contamination of the expanded cell product, including possible contamination by bacteria, fungi, mycoplasmas and exogenous viruses^[12]. Bacterial contamination remains one of the major risks

associated with blood product transfusion and is known to cause severe transplantation-related infections^[13]. Contamination of a cellular product may lead to transplantation failure or death of transplanted patient. This notion is supported by reports from the French Hemovigilance system demonstrating that between 1994 and 1998 transplantation associated bacterial infection was responsible for 22% of fatal cases associated with transplantation^[14]. Most Drug Administrations have, therefore, taken notice of this problem and defined that there should be no exogenous factor contamination in cellular products^[15-17]. Given all the considerations mentioned above, cellular products should be examined carefully to reduce the possibility of contamination before clinical transplantation.

In this paper, human BM-MSCs were used as feeder layer to support the expansion of HS/PCs from UCB in a serum-free culture system (the serum-free co-culture system). The proliferation potential of HS/PCs was analyzed. The expanded HS/PCs were suspended in L-15 medium to prepare the HS/PC product. Possible contamination by bacteria, fungi and mycoplasmas, the infection of exogenous virus, the concentration of bacterial endotoxin, and the SCF residual in HS/PC product were analysed. Finally, cells from the HS/PC product, with or without BM-MSCs, were transplanted into irradiated NOD/SCID mice to determine their *in vivo* engraftment potential.

MATERIALS AND METHODS

Preparation of BM-MSCs

Bone marrow (BM) was provided by the First Affiliated Hospital, Zhejiang University, and was approved by the Ethics Committee of Hospital. All donors had given informed consent before collection of bone marrow. The collected BM was washed three times with phosphate buffered saline (PBS). The cell pellet was re-suspended in α -MEM (Gibco, Hangzhou, China), and then loaded on Ficoll density gradient fractionation columns (density = 1.077 g/L, Dingguo, Hangzhou, China). Cells were centrifuged at $300 \times g$ for 25 min. The mononuclear cells (MNCs) in the interface were collected and washed three times with PBS. MNCs were re-suspended in MesenCult[®] 05401 medium (StemCell, Hangzhou, China), the cell density adjusted to 5×10^6 /mL, and cells seeded in the 25-culture flask. After culture of 3 d in 100% humidified 5% CO₂ at air 37°C, the cells were demi-replaced with fresh medium and cultured for another 3 d. Then, the medium was totally replaced with fresh medium every 3 d. At 90% confluence, the cells were detached by trypsin-EDTA (Gibco) and seeded into the 175-culture flask at a density of 1.4×10^6 cells as passage 1. The cells in passage 2 or 3 were used for co-culture with HS/PCs from UCB.

Co-culture of HS/PCs with BM-MSCs

UCBs were obtained from normal full-term deliveries in the Second Peoples' Hospital, Zhejiang University, as approved by the Ethics Committee of Hospital. Parturient women gave written consent for the use of UCB for research purposes. Collected UCB was heparinized to a

final heparin concentration of 20 U/mL.

MNCs in UCB were isolated using Ficoll density gradient centrifugation. The red blood cells (RBCs) were depleted by a 3% gelatin (Sigma, Hangzhou, China) sedimentation method. The leukocyte-rich fraction was washed with PBS to remove the gelatin, and then loaded on Ficoll density gradient fractionation columns (density = 1.077g/L, Dingguo). Cells were centrifuged at $300 \times g$ for 25 min. MNCs at the interface were collected and washed three times with PBS, and then re-suspended in serum-free Stem Span H3000 (StemCell) medium.

MNCs from UCB were seeded at a density of 1×10^5 cells/mL in the 175-culture flask with the confluent BM-MSCs. The medium for MNC culture was Stem Span H3000 containing SCF (50 ng/mL, Peprotech, Beijing, China), TPO (10 U/mL, Sansheng, Shenyang, China) and G-CSF (50 ng/mL, Jiuyuan, Hangzhou, China). After culture in 100% humidified 5% CO₂ at air 37°C for 10 d, the non-adherent cells in the culture medium were collected and analyzed for cell growth, flow cytometry characteristics and colony-forming units. The co-culture system with 10% FBS and three cytokines (see above) with- and without- BM-MSCs were used as Control 1 culture system and Control 2 culture system respectively.

Analysis of ex vivo expanded HS/PCs from UCB

The MNCs from UCB and the cells expanded in co-culture system for 10 d were analysed for cell surface CD34 antigen by the FACScalibur flow cytometer (Becton Dickinson, Beijing, China). The collected cells were diluted to 1×10^6 cells/mL with PBS containing 1%BSA. 10 μ L of antigens was added to 100 μ L samples and the cells were incubated for 30 min at 37°C. After washing once with PBS, the cells were re-suspended in 0.5 mL PBS and stained with mouse anti-human CD34-FITC and IgG1-FITC (Immunotech, Shanghai, China).

Granulocyte-macrophage colony-forming cells (GM-CFCs) and erythroid colony-forming cells (E-CFCs) were quantified in semisolid culture as follows: (1) GM-CFCs: cells were seeded at a density of 1×10^5 cells/mL in 2 mL of IMDM (Gibco) containing 2.7% methylcellulose and 100 ng/mL GM-CSF (Peprotech), and incubated at 37°C with 5% CO₂ for 14 d; and (2) E-CFCs: cells were seeded at the same density in 2 mL of IMDM containing 2.7% methylcellulose, 1×10^{-4} M 2-mercaptoethanol(Sigma,Shanghai, China), 3% glutamine (Sigma), 2 U/mL EPO (Peprotech), and incubated at 37°C with 5% CO₂ for 14 d. The colonies were counted by three persons in two different laboratories to reduce errors.

Determination of contamination in HS/PC product

The expanded HS/PCs from UCB were collected and washed three times with PBS, re-suspended with L-15 medium containing 10% dimethyl sulfoxide (DMSO, Gaylord, Shanghai, China) at a density of 1×10^7 cells/mL, and then transferred into the 5 mL cryovial as the HS/PC product. The pre-clinical safety of the HS/PC product was evaluated according to the Pharmacopoeia of the

People's Republic of China (PC, 2005 Edition).

A direct inoculation method was used to determine the possible contamination of the HS/PC products with bacteria, fungi and mycoplasmas. The HS/PC product was centrifuged at $300 \times g$ for 10 min, and the supernatant was collected and cultured in Thioglycollate Medium (Sanyao, Beijing, China) for more than 14 d at 35°C to determine possible contamination by bacteria, in Modified Martin Broth Medium (Sanyao) for more than 14 d at 25°C to determine possible contamination by fungi, and in Mycoplasma Broth Base Medium (Sanyao) for 21 d at 37°C to determine possible contamination by mycoplasmas.

Possible infection by exogenous virus was determined by *in vitro* culture, inoculation in SPF mice (Zheda, Hangzhou, China) and inoculation in avian embryos (Yibang, Hangzhou, China). For the *in vitro* culture, the cell suspension of HS/PC product was seeded at a density of 1×10^7 cells per well in a 6-well plate with confluent human fibroblast cells for 7 d at 37°C with 5% CO₂. Then, the human fibroblast cells were collected and seeded at a density of 5×10^5 cells per well in the new 6-well plates to culture for 14 d. The morphology of human fibroblast cells was detected. For SPF mouse inoculation, a cell suspension with 1×10^7 of expanded HS/PCs was transplanted into the brain and cavum peritoneaei of SPF mice. L-15 medium was used as control. At the 21th d, the physiological reaction of mice was examined. For avian embryo inoculation, a cell suspension with 1×10^7 of expanded HS/PCs and injected into the allantoic cavity of 9-11 d old avian embryos and the yolk sac of 5-6 d old avian embryos. 5 avian embryos were used for each group. After 5 d, the survival of the avian embryos was determined.

Detecting the bacterial endotoxin concentration

The bacterial endotoxin test (BET) method was used to detect the bacterial endotoxin concentration. Briefly, 4 solutions were prepared as follows: A solution used for the sample test [dilution of test sample no more than maximum valid dilution (MVD)], B solution used for the interfering test (control standard endotoxin (CSE, China National Biotec Group, Beijing, China) diluted with A solution), C solution used for the positive control [CSE diluted with tachypleus amebocyte lysate (TAL) Reagent Water (Zhanjiang A & C Biological LTD, Zhanjiang, China)], and D solution used for the negative control TAL Reagent Water(Zhanjiang).

According to PC (2005 edition, p365-368), the determining limitation (L) and MVD of the sample were calculated by the formulas: $L = K/M$ and $MVD = CL/\lambda$ [C: the concentration of sample. L is expressed in EU/mL, λ : the sensitivity of TAL]. To recheck the TAL sensibility, CSE was diluted with TAL Reagent Water to 0.25, 0.125, 0.063 and 0.032 EU/mL according to TAL ($\lambda = 0.125$ EU/mL). 0.1mL of diluted solution, with 2 replicates per concentration, was placed into a depyrogenated ampoule (Zhanjiang). D solution and C solution were used as negative and positive controls respectively. The ampoules with solution were incubated at 37°C for 60 min. Then, the ampoules were reversed and the formation of

gel was observed. A durable gel was determined as positive, a non-durable gel was determined as negative.

For the interfering test on the HS/PC product, CSE was diluted with HS/PC product at 48 dilutions in a series of solutions: 0.25, 0.125, 0.063 and 0.032 EU/mL with 2 replicates per concentration. TAL Reagent Water was used as the negative control. The ampoules with solution were incubated at 37°C for 60 min and the formation of gel in each sample was determined as above.

Detection of stem cell factor residual by ELISA

A Human Stem Cell Factor ELISA kit (B & D, Shanghai, China) was used, per manufacturers' instructions, to detect any residual stem cell factor (SCF) in HS/PC product. Briefly, the wells in an ImmunoModule plate were coated with a mouse anti-human SCF mAb overnight. Then, the wells were rinsed with PBS and blocked with 1% BSA for 2-4 h. The wells were rinsed and dried, and then the plate was stored at 4°C. After an overnight incubation (4°C), the wells were rinsed three times with the wash buffer. 100 μ L standards and 100 μ L supernatant from the expanded HP/SC product were applied to each well respectively and incubated for 1.5 h at 37°C. Then, the wells were rinsed 5 times with the wash buffer and 100 μ L biotinylated SCF per well was applied and incubated for 1 h at 37°C. After the wells were rinsed 5 times with wash buffer, 100 μ L horse radish peroxidase (HRP) per well was applied and incubated for 30 min at 37°C. The wells were rinsed 5 times with the wash buffer and incubated with 100 μ L tetramethyl benzidine (TMB) substrate per well at 37°C. After 5-20 min, the reaction was stopped with 100 μ L stop solution per well, and the results were read at 450 nm on a Dynatech Plate Reader (Biotech Instrument, Shanghai, China).

Engraftment assay of HS/PC products in NOD/SCID mice

The transplantation of the HS/PC product expanded from UCB in the serum-free co-culture system and the combination transplantation of HS/PCs expanded from UCB and BM-MSCs harvested from serum-free co-culture system was performed as previously described^[18], with slight modifications. Briefly, 8-wk-old male NOD/SCID mice were obtained from the Beijing Institute for Experimental Animals, CAS. All animals were handled under sterile conditions and maintained under microisolators in the animal facility located at The Center of Experimental Animals, Zhejiang University. All animal experiments were approved by the Institutional Animal Care and Use Committee and Animal Ethics Committee of Zhejiang University. At 24 h before transplantation, 100 μ L peripheral blood was collected from NOD/SCID mice by cutting the tail and diluted up to 250 μ L with PBS/1% HSA to detect the baseline of WBCs using Advia 120 (Bayer, Leverkusen, Germany). Then, mice were irradiated with a ⁶⁰Co in a split dose with a 4 h interval between doses. Each dose consisted of 15 min at 14.5 r/min. The expanded cells were transplanted by tail-vein injection into the irradiated NOD/SCID mice. Group A ($n = 22$ mice) was transplanted with cells from the HS/PC product, Group B ($n = 25$ mice) was transplanted

with cells from the HS/PC product and BM-MSCs from serum-free co-culture system, and Group C ($n = 18$ mice) was injected with the same volume (200 μ L) of PBS/1% HAS (irradiation control). In the Group A, the number of transplanted cells for each irradiated mouse was 8.5×10^5 cells in 200 μ L suspension. In the Group B, the 200 μ L of transplanted cells were composed of 6.0×10^5 cells from the HS/PC product and 2.5×10^5 cells of BM-MSCs from serum-free co-culture system. Starting on 3 d after transplantation and at subsequent regular intervals, 100 μ L peripheral blood was collected by retro orbital sampling from each mouse. The recovery of WBCs in the peripheral blood was analyzed as above. The surviving recipients were killed 30 d after transplantation, and the bone marrow (from the femurs and tibiae) was harvested. Real-time PCR (RT-PCR) analysis using human-specific Alu sequence primers was performed for cells harvested from the bone marrow of recipients as described previously^[18]. The GAPDH mRNA was used as a housekeeper gene to normalize the threshold cycle measurements for the Alu product. Result were shown as the concentration ratio of PCR product to that of GAPDH mRNA. We also detected human CD45⁺ cells in the bone marrow of transplanted mice using flow cytometry.

Statistics

Results are expressed as mean \pm SE, and statistical comparisons were performed using the one-way analysis of variance (ANOVA). A *P*-value of less than 0.05 was considered significantly different.

RESULTS

Support of BM-MSCs to ex vivo expansion of HS/PCs from UCB in the serum-free culture system

MNCs from human UCB were cultured in the serum-free co-culture system for 10 d. The co-culture system with serum (Control 1 culture system) and the culture system without BM-MSCs (Control 2 culture system) were used as controls. The *ex vivo* proliferation kinetics of non-adherent cells in three culture systems are shown in Figure 1A (day 0 to day 5) and 1B (day 5 to day 10). In the serum-free co-culture system, the total nuclear cells (TNCs) decreased gradually until the 4th d. Then, TNCs increased and grew during the lag period. TNCs in Control 1 culture system showed similar growth kinetics to TNCs in the serum-free co-culture system. After 10 d of culture, there was no significant difference in proliferation potentials between these two systems ($1.25 \pm 0.42 \times 10^7$ cells/mL for the serum-free co-culture system and $1.60 \pm 0.70 \times 10^7$ cells/mL for the Control 1 culture system, $P > 0.05$). The proliferation potential of TNCs in the Control 2 culture system was significantly lower than in the serum-free co-culture system ($0.93 \pm 0.31 \times 10^7$ cells/mL for the Control 2 culture system, $P < 0.05$).

The MNCs from UCB and the cells expanded in the three culture systems for 10 d were evaluated for cell surface CD34 antigen by the flow cytometry. In pre-expansion, the ratio of CD34⁺ cells in the MNCs was $1.8\% \pm 0.3\%$ (Figure 1C). After 10 d of culture, the ratios of CD34⁺ cells in the




Figure 1 Serum-free co-culture system improves the proliferation of hematopoietic/progenitor stem cells. A: the *in vitro* expansion kinetics of hematopoietic/progenitor stem cells (HS/PCs) in three culture systems between day 0 and day 5; B: The *in vitro* expansion kinetics of HS/PCs in three culture systems between day 5 and day 10; C: The ratio of CD34^+ cells in the mononuclear cells (MNCs) before expansion; D: The ratio of CD34^+ cells in the MNCs after expansion in the serum-free co-culture system; E: The expansion of granulocyte-macrophage colony-forming cells (GM-CFCs) and erythroid colony-forming cells (E-CFCs) before and after expansion. ^a $P < 0.05$. TNCs: Total nuclear cells.

serum-free co-culture system, the Control 1 culture system and the Control 2 culture system were $0.62\% \pm 0.19\%$ (Figure 1D), $0.49\% \pm 0.15\%$ and $0.23\% \pm 0.09\%$ respectively (data not shown). According to the calculation of total CD34^+ cells/mL, CD34^+ cells increased 43.3-fold in the serum-free co-culture system, 43.5-fold in the Control 1 culture system and 11.8-fold in the Control 2 culture system.

Granulocyte-macrophage colony-forming cell (GM-CFC) and erythroid colony-forming cell (E-CFC) assays were performed with non-adherent cells at the beginning and the termination of culture. As shown in Figure 1E, the serum-free co-culture system and the Control 1 cul-

ture system showed greater increase in GM-CFCs and E-CFCs than the Control 2 culture system ($P < 0.05$). The mean number of GM-CFCs and E-CFCs in the starting MNC cell fraction was $15.6 \pm 3.2/10^5$ and $14.3 \pm 2.5/10^5$, respectively. After expansion, there were $51.2 \pm 12.3/10^5$ GM-CFCs and $67.6 \pm 15.5/10^5$ E-CFCs in the serum-free co-culture system, $57.4 \pm 13.4/10^5$ GM-CFCs and $71.8 \pm 14.1/10^5$ E-CFCs in the Control 1 culture system, and $35.2 \pm 9.7/10^5$ GM-CFCs and $40.4 \pm 8.6/10^5$ E-CFCs in the Control 2 culture system. In the serum-free co-culture system, GM-CFCs increased 3.3-fold and E-CFCs increased 4.7-fold.

Analysis of Pre-clinical safety

The expanded HS/PCs from UCB were collected and re-suspended at a density of 1×10^7 cells/mL in L-15 medium to prepare the HS/PC product. The direct inoculation method was used to determine possible contamination of the HS/PC product by bacteria, fungi and mycoplasmas. After inoculation of the supernatant from the HS/PC product in Thioglycollate Medium and Modified Martin Broth Medium for more than 14 d and in Mycoplasma Broth Base Medium for 21 d to detect possible contamination by bacteria, fungi and mycoplasmas respectively. Results showed no contamination of the HS/PC product.

To determine possible infection of the HS/PC product by exogenous viruses, the cell suspension of HS/PC product was evaluated by *in vitro* culture with the human fibroblast cells. Figure 2A and B shows that the cell suspension of the HS/PC product had no effect on the cellular morphology and growth potential of human fibroblast cells. Inoculation experiments on SPF mice inoculation and on avian embryos failed to detect any abnormalities according to the Pharmacopoeia of the People's Republic of China (PC, 2005 Edition, p363-364), the HS/PC product was determined to contain no infection of exogenous virus.

The BET method was used to detect the possible bacterial endotoxin concentration. The determining limitation (L) was calculated using the formula $L = K/M$ and found to be 6 EU/mL, so MVD was 48. Then, the recheck of TAL sensitivity was calculated using $\lambda c = \lg^{-1}(\Sigma X/4)$, determined to be 0.204. Because λc was between 2.0-0.5 λ (0.25-0.06 EU/mL), TAL sensitivity was qualified as per Table 1. For the interfering test of the HS/PC product, ES was determined between 2.0-0.5 λ (0.25-0.06 EU/mL) when tested with 0.125 EU/mL TAL. There was no interference of the HS/PC product with 48 dilutions as per Table 2. Therefore, the bacterial endotoxin concentration of HS/PC product did not exceed the test limitation (6 EU/mL, see Table 3).

Residual SCF in the HS/PC product was detected by ELISA. A standard curve was constructed by plotting the mean absorbance for each standard against the concentration and a best fitting curve was drawn (Figure 2C). From this standard curve, the residual SCF in the HS/PC product was calculated as 75 pg/mL. This was greatly reduced in comparison with the 50 ng/mL of exogenous SCF added in the serum-free co-culture system.

Assay of HS/PC product reconstituting hematopoietic progenitors in NOD/SCID mice

The *in vivo* engraftment potential of cells from the HS/PC product in NOD/SCID mice was determined with three transplantation treatments, as described in Materials and Methods. All mice in the control group (Group C) were dead within 12 d. In transplantation Group A, two mice died at the 13th d, and two mice died on the 15th and 17th d after transplantation, respectively. In the transplantation Group B, two mice died on the 20th and 23th d after transplantation, respectively. The numbers of white blood cells (WBCs) in mice after transplantation are shown in Figure 3A. The number of WBCs in mice trans-




Figure 2 The determination of exogenous virus and stem cell factor residual in hematopoietic/progenitor stem cell product. A: The cellular morphology of human fibroblasts cultured in α -MEM ($\times 400$); B: The cellular morphology of human fibroblasts cultured in α -MEM with the cell suspension of hematopoietic/progenitor stem cell (HS/PC) product ($\times 400$); C: The standard curve of residual stem cell factor (SCF) in the HS/PC product. It was detected by ELISA. After a curve (dotted line) was constructed by plotting the mean absorbance against the concentration, a best fitting curve (solid line) through the points on the graph was drawn.

planted only with cells from the HS/PC product (Group A) decreased until the 18th d after transplantation. Then, WBCs increased and reached baseline pretreatment levels at 27-29 d after transplantation. WBCs in mice transplanted with the combination of HS/PCs and BM-MSCs (Group B) showed similar growth dynamics to Group A. However, the recovery of hematopoiesis was faster than that of Group A. WBCs in mice of Group B started increasing on the 15th d and reached baseline pretreatment levels on the 24th d after transplantation.

Thirty days after transplantation, mice were killed and

Table 1 Recheck of tachypleus amebocyte lysate sensibility

Tube	C solution (EU/mL)				D solution	Ending concentration	× (lg ending con)
	0.25	0.125	0.063	0.032			
1	+	+	-	-	-	0.125	-0.921
2	+	+	-	-	-	0.125	-0.921
3	+	+	+	-	-	0.060	-1.200
4	+	+	-	-	-	0.125	-0.921

Table 2 Interfering test of cellular product

TAL (0.125 EU/mL)	Bacterial endotoxin concentration (EU/mL)								Negative control		E (EU/mL)
	0.25		0.125		0.063		0.032				
A solution	+	+	+	+	-	-	-	-	-	-	0.125
B solution	+	+	-	-	-	-	-	-	-	-	0.250
C solution	+	+	-	-	-	-	-	-	-	-	0.250

Table 3 Bacterial endotoxin concentration of cellular product (48 dilutions)

Group	Result	
A solution	-	-
B solution	+	+
C solution	+	+
D solution	-	-

bone marrow was collected to determine the homing of human cells in the bone marrow. RT-PCR analysis demonstrated the presence of human hematopoietic cells in the bone marrow of NOD/SCID mice transplanted with cells from the HS/PC product and with the combination of expanded HS/PCs and BM-MSCs. However, the expression level of the human *Alu* gene and the percentage of human CD45⁺ cells in the bone marrow of mice transplanted with the combination of expanded HS/PCs and BM-MSCs was significantly higher than that of mice transplanted with only HS/PCs from UCB ($P < 0.05$) (Figure 3B and C). As a negative control, the expression of human the *Alu* gene in normal mouse bone marrow was not detected (data not shown).

DISCUSSION

Co-culture with BM-MSCs can promote the expansion of HS/PCs. BM-MSCs provide biological support for HS/PCs by constitutively secreting cytokines important for HS/PC differentiation, including interleukin (IL)-1, IL-6, IL-7, IL-8, IL-11, IL-12, IL-14, IL-15, IL-27, leukemia inhibitory factor (LIF), Flt-3 ligand, SCF, G-CSF and GM-CSF^[19]. Another important characteristic of BM-MSCs that relates to hematopoiesis is cell-to-cell contact. BM-MSCs express surface molecules that can interact with cells of the hematopoietic lineage, including Intercellular Adhesion Molecule (ICAM)-1 (CD54), ICAM-2 (CD102), Vascular Cell Adhesion Molecule (VCAM-1, CD106),

Lymphocyte Function-associated Antigen 3 (LFA-3, CD58), Activated Leukocyte Cellular Adhesion Molecule (ALCAM, CD166), Hyaluronate Receptor (HCAM, CD44) and integrins such as Very Late Antigen (VLA, CD49)^[20]. Through interaction with adhesion molecules, the HS/PCs can adhere to the BM-MSCs, and direct contact is essential for the expansion of HS/PCs. The study by Kawad *et al.*^[4] showed that not only the effectiveness of *in vitro* expansion by direct contact of HS/PCs with BM-MSCs is higher than the no contact control, but also the area of direct contact has a positive correlation with the effectiveness of HS/PC expansion. This suggested that there might be an essential ligand-accepter relationship between the cellular membrane surfaces of BM-MSCs and HS/PCs. Only after contact between the cells, can the proliferation and differentiation of HS/PCs be regulated by the ligand-accepter effect. Nowadays, when HS/PCs are cultured and expanded *in vitro*, BM-MSCs are always used as a feeder layer combining with cytokines to promote the efficiency of HS/PC amplification. Here, the expansion levels of HS/PCs from UCB in two co-culture systems with BM-MSCs as the feeder layer were higher than that in the culture system without BM-MSCs, confirming that BM-MSCs supported the expansion of HS/PCs through providing a hematopoietic microenvironment. In determining the proliferation potential of HS/PCs, we analyzed only the expansion level of cells suspended in the medium, although there was the evidence of HS/PC-derived cobblestone-forming hematopoietic cells beneath the BM-MSC layer^[21]. However, the expansion levels of TNCs, CD34⁺ cells and colony-forming cells suspended in the medium were enough to demonstrate the capacity of BM-MSCs for supporting the *ex vivo* expansion of HS/PCs from UCB.

Bovine serum or equine serum is always added during *in vitro* expansion of HS/PCs. Therefore, there may be residual serum albumin (SA) in cellular products. SA is a sensitizer to humans which may affect the human immune system. There are two main ways to solve this




Figure 3 Engraftment of cells from hematopoietic/progenitor stem cell product in NOD/SCID mice. A: The recovery of WBC population in irradiated NOD/SCID mice transplanted with the expanded hematopoietic/progenitor stem cells (HS/PCs) and the combination of expanded HS/PCs and BM-mesenchymal stem cells (MSCs). Group A: WBC of mice transplanted with expanded HS/PCs, Group B: WBC of mice transplanted with the combination of expanded HS/PCs and BM-MSCs, Group C: WBC of mice in the control group. BL: Baseline of WBCs before irradiation; B: RT-PCR detection of human-specific Alu sequence fragment in NOD/SCID mice bone marrow. The GAPDH mRNA was used as a housekeeper gene to normalize the threshold cycle measurements for the Alu product. The result was showed as the concentration ratio of PCR product to that of GAPDH mRNA. $^aP < 0.05$; C: The percentage of human CD45⁺ cells in the bone marrow of mice detected by the flow cytometry. White diamond indicates the percentage of human CD45⁺ cells in the bone marrow of mice transplanted with the combination of HS/PC product and BM-MSCs. Black diamond indicates the percentage of human CD45⁺ cells in the bone marrow of mice transplanted only with HS/PC product.

problem: (1) use of SFM (serum-free medium); and (2) limiting residual bovine serum. We use BM-MSCs as a feeder layer to co-culture MNCs from UCB in a serum-free culture system supplemented with three cytokines.

Our results showed that the difference in CD34⁺ cells and colony-forming cell expansion potential between the two co-culture systems with and without serum was not statistically significant although the number of TNCs expanded in the serum-free co-culture system was less than that in the co-culture system with serum. However, the degree of expansion of TNCs, CD34⁺ and colony-forming cells in the serum-free co-culture system were higher than in the culture system without BM-MSCs. We can infer that BM-MSCs support the *ex vivo* expansion of HS/PCs, especially the *ex vivo* expansion of hematopoietic stem cells (HSCs). Therefore, the serum-free co-culture system with BM-MSCs can be recommended for culture of HS/PCs from UCB for clinical transplantation.

BM-MSCs have become the attractive for clinical use due to their multi-differentiation potential, easy isolation and culture as well as for their high *ex vivo* expansive potential^[20,22]. Co-transplantation of BM-MSCs is capable of enhancing engraftment of HS/PCs in a fetal sheep model^[23-25], suggesting that co-transplantation of BM-MSCs and HS/PCs from human UCB results in the acceleration of short-, medium- and long-term engraftments of HS/PCs. Our experiments on transplantation in NOD/SCID mice indicated the reconstituting ability of expanded HS/PCs in the irradiated mice. The co-transplantation of expanded HS/PCs with BM-MSCs from the serum-free co-culture system promoted greater engraftment of HS/PCs in recipients in comparison to the transplantation of HS/PCs expanded alone. It is thought that BM-MSCs enhance engraftment and support hematopoiesis by mechanisms that may promote either homing or proliferation of HS/PCs through release of cytokines^[20]. It is well known that stromal derived factor (SDF)-1 has significant importance in the homing of HS/PCs to their niche in the bone marrow. It was demonstrated that SDF-1 effects the recruitment of CD34⁺ cells to the marrow in a NOD/SCID model of human hematopoiesis^[19]. Thus, BM-MSCs have a role in homing both by inducing the expression of SDF-1 via secretion of stromal cell factor (SCF), and directly by secretion of SDF-1. Primary BM-MSCs derived from adult sources promote the engraftment of UCB-derived CD34⁺ cells to a similar degree as culture-expanded BM-MSCs, indicating that the biological properties of primary BM-MSCs are preserved during expansion. This important for the safety of culture-expanded cells in potential therapeutic application^[26].

A series of studies indicates that BM-MSCs escape recognition by alloreactive cells, and are immune privileged^[27]. BM-MSCs generally express only HLA class I. Despite a few studies suggesting that BM-MSCs could be induced by IFN- γ to up-regulate the expression of HLA class II, neither the BM-MSCs that expressed HLA class I only, nor the BM-MSCs that expressed both HLA class I and class II induced by IFN- γ , showed immunogenic potential. Furthermore, both cell types could inhibit T cell immune responses, and the up-regulation of HLA class II by IFN- γ did not elicit a proliferative response of T cells^[27,28]. BM-MSCs have been shown both *in vivo*^[29,30] and *in vitro*^[31,32] to suppress T cell activation. Additionally, BM-MSCs have been shown to suppress the proliferation

of activated T cells induced by allo-antigens in the mixed lymphocyte reaction (MLR)^[51] or induced by mitogens such as phytohemagglutinin^[33], or concanavalin A^[27], as well as the activation of T cells by CD3 and CD28 antibody stimulation^[34]. Several studies have shown similar effects when using BM-MSCs that are autologous or allogeneic to the responder cells, indicating a genetically unrestricted suppression^[19]. Having low immunogenicity, BM-MSCs have no requirement for HLA matching and should, therefore, be considered for co-transplantation with HS/PCs in therapeutic applications.

Patients with hematologic malignancies must undergo a flushing dose of radiotherapy or chemotherapy before HSCT treatment, in order to eliminate cancer cells that could otherwise cause the killing of bone marrow cells and inhibition of the activity of immune cells. Therefore, the contamination of the expanded cellular product could result in serious post-transplantation infection in recipients. Bacterial endotoxin, released by Gram-negative bacteria, is an exogenous pyrogen that can activate heterophil granulocytes to release an endogenous pyrogen which will cause fever by acting upon the body's temperature regulating center^[35]. The expanded cellular product must be rigorously controlled before transplantation to make sure that it is free from xenogenic cell pathogens and exogenous contaminants from isolation and culture of cells which could jeopardize the patient. The HS/PC product of the serum-free co-culture system was tested for the possibility of contamination by exogenous pathogens and other material according to the PC and China Biological Regulations. The results showed that there was no contamination or infection present in the HS/PC products. In the culture system used, three cytokines were added to the medium. TPO and G-CSF used in the culture system were commercial products approved for clinical application. Because the SCF used in the culture system was only approved for laboratory application, the content of residual SCF in the HS/PC product was determined. The results showed that the levels of endotoxin and residual SCF in the HS/PC products were below the allowed limits. These safety standards will be applied in the preparation of HS/PC products for clinical transplantation.

COMMENTS

Background

Umbilical cord blood transplantation (UCBT) has been used in treatment of hematologic malignancies, aplastic anemia, hemoglobinopathies, and severe combined immunodeficiency and so on. However, the low quantity of hematopoietic/progenitor stem cells (HS/PCs) in UCB may lead to the failure of transplantation, and the contamination of the cellular product could even cause death of transplanted patient. Therefore, for the clinical application of UCB it is important to prepare sufficient HS/PCs from UCB that are contamination-free, according to clinical standards.

Research frontiers

In recent years, co-culture HS/PCs with BM-MSCs has been used to expand HS/PCs. Bone marrow-mesenchymal stem cells (BM-MSCs) can secrete various soluble factors and provide the direct cell-cell contact, which are important to the proliferation and differentiation of HS/PCs. However, the cell product harvested from co-culture system is prone to be contaminated. So, before transplantation, it should be carefully determined whether there is any contamination of the HS/PC product by bacteria, fungi, mycoplasmas or exogenous viruses,

and whether the transplantation of the HS/PC product is effective for therapeutic applications.

Innovations and breakthroughs

In this study, the authors used the co-culture system to improve the proliferation and differentiation of HS/PCs. Through the stringent control of the co-culture system, such as in the quality of both the HS/PCs and BM-MSCs, the amount of the cytokines and the time of co-culture, the TNCs and CD34⁺ cells were greatly increased. This HS/PC product is safe for clinical transplantation, without any contamination by bacteria, fungi and mycoplasmas, and with concentrations of bacterial endotoxin and residual SCF residual which are too low to be harmful. Because of the high quality of our product, the rapid engraftment of hematopoietic cells can be effectively established, as demonstrated by the transplantation experiments in mice.

Applications

This research has finally established an efficient and safe way to expand HS/PCs, which can effectively achieve the rapid engraftment of hematopoietic cells. Using this method, the authors have produced the HS/PC product, and its high quality has been acknowledged by the National Institutes for Food and Drug Control. So, this research provides both the theoretical and experimental foundation for the clinical application of this HS/PC product.

Peer review


This research provides a procedure for effectively expansion of HS/PCs, and confirms that HS/PC product is clinically safe for clinical transplantation. The HS/PC product is efficient in the rapid engraftment of hematopoietic cells.

REFERENCES

- 1 **Gluckman E.** Current status of umbilical cord blood hematopoietic stem cell transplantation. *Exp Hematol* 2000; **28**: 1197-1205
- 2 **Kurtzberg J,** Laughlin M, Graham ML, Smith C, Olson JF, Halperin EC, Ciocchi G, Carrier C, Stevens CE, Rubinstein P. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. *N Engl J Med* 1996; **335**: 157-166
- 3 **da Silva CL,** Gonçalves R, dos Santos F, Andrade PZ, Almeida-Porada G, Cabral JM. Dynamic cell-cell interactions between cord blood haematopoietic progenitors and the cellular niche are essential for the expansion of CD34⁺, CD34⁺CD38⁻ and early lymphoid CD7⁺ cells. *J Tissue Eng Regen Med* 2010; **4**: 149-158
- 4 **Kawada H,** Ando K, Tsuji T, Shimakura Y, Nakamura Y, Chargui J, Hagiwara M, Itagaki H, Shimizu T, Inokuchi S, Kato S, Hotta T. Rapid ex vivo expansion of human umbilical cord hematopoietic progenitors using a novel culture system. *Exp Hematol* 1999; **27**: 904-915
- 5 **Wang JF,** Wang LJ, Harrington J, McNiece I K. Effects of bone marrow-derived mesenchymal stem cell layer on expansion and differentiation of hematopoietic stem cells from cord blood. *J Zhejiang Univer (Sci Ed)* 2003; **30**: 93-97
- 6 **Kadereit S,** Deeds LS, Haynesworth SE, Koc ON, Kozik MM, Szekely E, Daum-Woods K, Goetichius GW, Fu P, Welniak LA, Murphy WJ, Laughlin MJ. Expansion of LTC-ICs and maintenance of p21 and BCL-2 expression in cord blood CD34⁺/CD38⁻ early progenitors cultured over human MSCs as a feeder layer. *Stem Cells* 2002; **20**: 573-582
- 7 **Koh SH,** Choi HS, Park ES, Kang HJ, Ahn HS, Shin HY. Co-culture of human CD34⁺ cells with mesenchymal stem cells increases the survival of CD34⁺ cells against the 5-azadeoxycytidine- or trichostatin A-induced cell death. *Biochem Biophys Res Commun* 2005; **329**: 1039-1045
- 8 **Li N,** Feugier P, Serrurier B, Latger-Cannard V, Lesesve JF, Stoltz JF, Eljaafari A. Human mesenchymal stem cells improve ex vivo expansion of adult human CD34⁺ peripheral blood progenitor cells and decrease their allostimulatory capacity. *Exp Hematol* 2007; **35**: 507-515
- 9 **Fujimoto N,** Fujita S, Tsuji T, Toguchida J, Ida K, Suganami H, Iwata H. Microencapsulated feeder cells as a source of soluble factors for expansion of CD34⁺ hematopoietic stem

- cells. *Biomaterials* 2007; **28**: 4795-4805
- 10 **Fei XM**, Wu YJ, Chang Z, Miao KR, Tang YH, Zhou XY, Wang LX, Pan QQ, Wang CY. Co-culture of cord blood CD34(+) cells with human BM mesenchymal stromal cells enhances short-term engraftment of cord blood cells in NOD/SCID mice. *Cytotherapy* 2007; **9**: 338-347
- 11 **Chen X**, Xu H, Wan C, McCaigue M, Li G. Bioreactor expansion of human adult bone marrow-derived mesenchymal stem cells. *Stem Cells* 2006; **24**: 2052-2059
- 12 **Goldman M**, Sher G, Blajchman M. Bacterial contamination of cellular blood products: the Canadian perspective. *Transfus Sci* 2000; **23**: 17-19
- 13 **Ribault S**, Faucon A, Grave L, Nannini P, Faure IB. Detection of bacteria in red blood cell concentrates by the Scan-system method. *J Clin Microbiol* 2005; **43**: 2251-2255
- 14 **Andreu G**, Morel P, Forestier F, Debeir J, Rebibo D, Janvier G, Hervé P. Hemovigilance network in France: organization and analysis of immediate transfusion incident reports from 1994 to 1998. *Transfusion* 2002; **42**: 1356-1364
- 15 **WHO Expert Committee On Biological Standardization**. *World Health Organ Tech Rep Ser* 1998; **878**: i-vi, 1-101
- 16 **FDA**. Points to consider in the characterization of cell lines used to produce biologicals. 1993
- 17 Points to consider in the manufacture and testing of monoclonal antibody products for human use (1997). U.S. Food and Drug Administration Center for Biologics Evaluation and Research. *J Immunother* 1997; **20**: 214-243
- 18 **Huang GP**, Pan ZJ, Jia BB, Zheng Q, Xie CG, Gu JH, McNiece IK, Wang JF. Ex vivo expansion and transplantation of hematopoietic stem/progenitor cells supported by mesenchymal stem cells from human umbilical cord blood. *Cell Transplant* 2007; **16**: 579-585
- 19 **Rasmusson I**. Immune modulation by mesenchymal stem cells. *Exp Cell Res* 2006; **312**: 2169-2179
- 20 **Fibbe WE**, Noort WA. Mesenchymal stem cells and hematopoietic stem cell transplantation. *Ann N Y Acad Sci* 2003; **996**: 235-244
- 21 **Xie CG**, Wang JF, Xiang Y, Jia BB, Qiu LY, Wang LJ, Wang GZ, Huang GP. Marrow mesenchymal stem cells transduced with TPO/FL genes as support for ex vivo expansion of hematopoietic stem/progenitor cells. *Cell Mol Life Sci* 2005; **62**: 2495-2507
- 22 **Minguell JJ**, Erices A, Conget P. Mesenchymal stem cells. *Exp Biol Med* (Maywood) 2001; **226**: 507-520
- 23 **Anklesaria P**, Kase K, Glowacki J, Holland CA, Sakakeeny MA, Wright JA, FitzGerald TJ, Lee CY, Greenberger JS. Engraftment of a clonal bone marrow stromal cell line in vivo stimulates hematopoietic recovery from total body irradiation. *Proc Natl Acad Sci USA* 1987; **84**: 7681-7685
- 24 **Almeida-Porada G**, Flake AW, Glimp HA, Zanjani ED. Cotransplantation of stroma results in enhancement of engraftment and early expression of donor hematopoietic stem cells in utero. *Exp Hematol* 1999; **27**: 1569-1575
- 25 **Almeida-Porada G**, Porada CD, Tran N, Zanjani ED. Cotransplantation of human stromal cell progenitors into preimmune fetal sheep results in early appearance of human donor cells in circulation and boosts cell levels in bone marrow at later time points after transplantation. *Blood* 2000; **95**: 3620-3627
- 26 **in't Anker PS**, Noort WA, Kruisselbrink AB, Scherjon SA, Beekhuizen W, Willemze R, Kanhai HH, Fibbe WE. Nonexpanded primary lung and bone marrow-derived mesenchymal cells promote the engraftment of umbilical cord blood-derived CD34(+) cells in NOD/SCID mice. *Exp Hematol* 2003; **31**: 881-889
- 27 **Le Blanc K**, Tammik C, Rosendahl K, Zetterberg E, Ringdén O. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. *Exp Hematol* 2003; **31**: 890-896
- 28 **Klyushnenkova E**, Mosca JD, Zernetkina V, Majumdar MK, Beggs KJ, Simonetti DW, Deans RJ, McIntosh KR. T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. *J Biomed Sci* 2005; **12**: 47-57
- 29 **Kim DW**, Chung YJ, Kim TG, Kim YL, Oh IH. Cotransplantation of third-party mesenchymal stromal cells can alleviate single-donor predominance and increase engraftment from double cord transplantation. *Blood* 2004; **103**: 1941-1948
- 30 **Le Blanc K**, Rasmusson I, Sundberg B, Götherström C, Hassan M, Uzunel M, Ringdén O. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. *Lancet* 2004; **363**: 1439-1441
- 31 **Di Nicola M**, Carlo-Stella C, Magni M, Milanese M, Longoni PD, Matteucci P, Grisanti S, Gianni AM. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. *Blood* 2002; **99**: 3838-3843
- 32 **Sudres M**, Norol F, Trenado A, Grégoire S, Charlotte F, Levacher B, Lataillade JJ, Bourin P, Holy X, Vernant JP, Klatzmann D, Cohen JL. Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graft-versus-host disease in mice. *J Immunol* 2006; **176**: 7761-7767
- 33 **Li CD**, Zhang WY, Li HL, Jiang XX, Zhang Y, Tang PH, Mao N. Mesenchymal stem cells derived from human placenta suppress allogeneic umbilical cord blood lymphocyte proliferation. *Cell Res* 2005; **15**: 539-547
- 34 **Aggarwal S**, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. *Blood* 2005; **105**: 1815-1822
- 35 **National Pharmacopoeia Community**. 3rd ed. Appendix, Edition. Pharmacopoeia of the People's Republic of China, 2005: 360-368

S- Editor Wang JL L- Editor Hughes D E- Editor Ma WH



ACKNOWLEDGMENTS

Acknowledgments to reviewers of World Journal of Stem Cells

Many reviewers have contributed their expertise and time to the peer review, a critical process to ensure the quality of *World Journal of Stem Cells*. The editors and authors of the articles submitted to the journal are grateful to the following reviewers for evaluating the articles (including those published in this issue and those rejected for this issue) during the last editing time period.

Heli Teija Kristiina Skottman, PhD, Academy of Finland Research fellow, Regea Institute for Regenerative medicine, University of Tampere, Finland, Biokatu 12, 33520 Tampere, Finland

Soren Paludan Sheikh, MD, PhD, Professor, Department of Biochemistry, Pharmacology and Genetics, Odense University Hospital, University of Southern Denmark, Sdr. Boulevard 29, DK 5000, Denmark

Andre Van Wijnen, PhD, Department of Cell Biology, Rm S3-322, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA 01655, United States

Ludwig Aigner, PhD, Professor, Institute of Molecular Regenerative Medicine, Paracelsus Medical University, Strubergasse 21, A-5020 Salzburg, Austria

Borhane Annabi, PhD, Professor, Department of Chemistry, Biomed Research Centre, Université du Québec à Montréal Montreal, Quebec, H2X 2J6, Canada

Denis Corbeil, PhD, Tissue Engineering Laboratories, Biotech, Medical Faculty, Technical University of Dresden, Tatz-

berg 47-49, 01307, Dresden, Germany

Yusuke Furukawa, MD, PhD, Division of Stem Cell Regulation, Center for Molecular Medicine, Jichi Medical University School of Medicine, 3311-1 Yakushiji, Shimotsuke, Tochigi 329-0498, Japan

Mieke Geens, PhD, EMGE, UZ Brussel, Laarbeeklaan 101, 1090 Jette, Brussels, Belgium

Zhong-Chao Han, MD, PhD, Professor, Institute of Hematology, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China


Xiao-Yan Jiang, MD, PhD, Associate Professor, Medical Genetics, University of British Columbia, Senior Scientist, Terry Fox Laboratory, BC Cancer Agency Research Centre, 675 West 10th Avenue, Vancouver, BC V5Z 1L3, Canada

Hiroyuki Miyoshi, PhD, Subteam for Manipulation of Cell Fate, BioResourceCenter, RIKEN, 3-1-1 Koyadai, Tsukuba, Ibaraki 305-0074, Japan

Alice Pébay, PhD, Centre for Neuroscience & Department of Pharmacology, University of Melbourne, Parkville VIC 3010, Australia

John F Zhong, PhD, Assistant Professor, School of Medicine, University of Southern California, 2025 Zonal Ave, RMR 210, Los Angeles, CA 90033, United States

Hong Yu, PhD, Miami VA Health Care System, 1201 NW 16th St, Research 151, Miami, FL 33125, United States



Events Calendar 2011

March 26, 2011

Stem Cell Agency Governance
Subcommittee Meeting, Crowne
Plaza SFO, 1177 Airport Blvd,
Burlingame, CA,
United States

January 29-February 2, 2011
LabAutomation2011,
Palm Springs, CA, United States

February 4, 2011
7th annual Swiss Stem Cell Network
meeting, Swiss Federal Institute
of Technology in Lausanne,
Switzerland

March 1, 2011
The 6th Annual Stem Cell Summit,

11 Fulton Street, New York City, NY,
United States

March 22, 2011
StemCONN 2011, Farmington, CT,
United States

March 27-31, 2011
SBS 17th Annual Conference and
Exhibition, Orlando, FL, United States

April 6-8, 2011
EMBO Conference-Advances in
Stem Cell Research: Development,
Regeneration and Disease,
Institut Pasteur, Paris,
France

April 7-10, 2011
2011 CSHL Meeting on Stem Cell
Engineering & Cell Therapy, Cold

Spring Harbor Laboratory, Cold
Spring Harbor, NY, United States

April 25-26, 2011
International Conference on Stem
Cell Research, Hotel Equatorial
Penang, Malaysia

April 27, 2011
6th Annual Wisconsin Stem Cell
Symposium, BioPharmaceutical
Technology Center, Madison, WI,
United States

May 9-11, 2011
The World Stem Cells and
Regenerative Medicine Congress
2011, Victoria Park Plaza, London,
United Kingdom


May 23-24, 2011

The 4th Annual Israeli Stem Cell
Meeting, Beit Sourasky,
Chaim Sheba Medical Center,
Israel

May 26-27, 2011
7th annual Stem Cell Research &
Therapeutics Conference, Boston,
MA, United States

September 20-24, 2011
2011 CSHL Meeting on Stem
Cell Biology, Cold Spring
Harbor Laboratory, Cold Spring
Harbor, NY, United States

October 2011
3rd Annual World Stem Cells &
Regenerative Medicine
Congress Asia 2011, Seoul,
South Korea



INSTRUCTIONS TO AUTHORS

GENERAL INFORMATION

World Journal of Stem Cells (*World J Stem Cells*, *WJSC*, online ISSN 1948-0210, DOI: 10.4252), is a monthly, open-access (OA), peer-reviewed journal supported by an editorial board of 284 experts in stem cell from 28 countries.

The biggest advantage of the OA model is that it provides free, full-text articles in PDF and other formats for experts and the public without registration, which eliminates the obstacle that traditional journals possess and usually delays the speed of the propagation and communication of scientific research results. The open access model has been proven to be a true approach that may achieve the ultimate goal of the journals, i.e. the maximization of the value to the readers, authors and society.

Maximization of personal benefits

The role of academic journals is to exhibit the scientific levels of a country, a university, a center, a department, and even a scientist, and build an important bridge for communication between scientists and the public. As we all know, the significance of the publication of scientific articles lies not only in disseminating and communicating innovative scientific achievements and academic views, as well as promoting the application of scientific achievements, but also in formally recognizing the "priority" and "copyright" of innovative achievements published, as well as evaluating research performance and academic levels. So, to realize these desired attributes of *WJSC* and create a well-recognized journal, the following four types of personal benefits should be maximized. The maximization of personal benefits refers to the pursuit of the maximum personal benefits in a well-considered optimal manner without violation of the laws, ethical rules and the benefits of others. (1) Maximization of the benefits of editorial board members: The primary task of editorial board members is to give a peer review of an unpublished scientific article *via* online office system to evaluate its innovativeness, scientific and practical values and determine whether it should be published or not. During peer review, editorial board members can also obtain cutting-edge information in that field at first hand. As leaders in their field, they have priority to be invited to write articles and publish commentary articles. We will put peer reviewers' names and affiliations along with the article they reviewed in the journal to acknowledge their contribution; (2) Maximization of the benefits of authors: Since *WJSC* is an open-access journal, readers around the world can immediately download and read, free of charge, high-quality, peer-reviewed articles from *WJSC* official website, thereby realizing the goals and significance of the communication between authors and peers as well as public reading; (3) Maximization of the benefits of readers: Readers can read or use, free of charge, high-quality peer-reviewed articles without any limits, and cite the arguments, viewpoints, concepts, theories, methods, results, conclusion or facts and data of pertinent literature so as to validate the innovativeness, scientific and practical values of their own research achievements, thus ensuring that their articles have novel arguments or viewpoints, solid evidence and correct conclusion; and (4) Maximization of the benefits of employees: It is an iron law that a first-class journal is unable to exist without first-class editors, and only first-class editors can create a first-class academic journal. We insist on strengthening our team cultivation and construction so that every employee, in an open, fair and transparent environment, could contribute their wisdom to edit and publish high-quality ar-

ticles, thereby realizing the maximization of the personal benefits of editorial board members, authors and readers, and yielding the greatest social and economic benefits.

Aims and scope

The major task of *WJSC* is to report rapidly original articles and comprehensive reviews on basic laboratory investigations of stem cells and their application in clinical care and treatment of patients. *WJSC* is designed to cover all aspects of stem cells, including: Embryonic, neural, hematopoietic, mesenchymal, tissue-specific, and cancer stem cells; the stem cell niche; stem cell genomics and proteomics; and stem cell techniques and their application in clinical trials. Papers published in *WJSC* will cover the biology, culture, differentiation and application of stem cells from all stages of their development, from germ cell to embryo and adult.

Columns

The columns in the issues of *WJSC* will include: (1) Editorial: To introduce and comment on major advances and developments in the field; (2) Frontier: To review representative achievements, comment on the state of current research, and propose directions for future research; (3) Topic Highlight: This column consists of three formats, including (A) 10 invited review articles on a hot topic, (B) a commentary on common issues of this hot topic, and (C) a commentary on the 10 individual articles; (4) Observation: To update the development of old and new questions, highlight unsolved problems, and provide strategies on how to solve the questions; (5) Guidelines for Basic Research: To provide guidelines for basic research; (6) Guidelines for Clinical Practice: To provide guidelines for clinical diagnosis and treatment; (7) Review: To review systemically progress and unresolved problems in the field, comment on the state of current research, and make suggestions for future work; (8) Original Articles: To report innovative and original findings in stem cells; (9) Brief Articles: To briefly report the novel and innovative findings in stem cells; (10) Case Report: To report a rare or typical case; (11) Letters to the Editor: To discuss and make reply to the contributions published in *WJSC*, or to introduce and comment on a controversial issue of general interest; (12) Book Reviews: To introduce and comment on quality monographs of stem cells; and (13) Guidelines: To introduce consensus and guidelines reached by international and national academic authorities worldwide on the research in stem cells.

Name of journal

World Journal of Stem Cells

ISSN

ISSN 1948-0210 (online)

Indexed and Abstracted in

PubMed Central, PubMed, Digital Object Identifier, and Directory of Open Access Journals.

Published by

Baishideng Publishing Group Co., Limited

SPECIAL STATEMENT

All articles published in this journal represent the viewpoints of the

Instructions to authors

authors except where indicated otherwise.

Biostatistical editing

Statistical review is performed after peer review. We invite an expert in Biomedical Statistics from to evaluate the statistical method used in the paper, including *t*-test (group or paired comparisons), chi-squared test, Ridit, probit, logit, regression (linear, curvilinear, or stepwise), correlation, analysis of variance, analysis of covariance, *etc.* The reviewing points include: (1) Statistical methods should be described when they are used to verify the results; (2) Whether the statistical techniques are suitable or correct; (3) Only homogeneous data can be averaged. Standard deviations are preferred to standard errors. Give the number of observations and subjects (*n*). Losses in observations, such as drop-outs from the study should be reported; (4) Values such as ED50, LD50, IC50 should have their 95% confidence limits calculated and compared by weighted probit analysis (Bliss and Finney); and (5) The word 'significantly' should be replaced by its synonyms (if it indicates extent) or the *P* value (if it indicates statistical significance).

Conflict-of-interest statement

In the interests of transparency and to help reviewers assess any potential bias, *WJSC* requires authors of all papers to declare any competing commercial, personal, political, intellectual, or religious interests in relation to the submitted work. Referees are also asked to indicate any potential conflict they might have reviewing a particular paper. Before submitting, authors are suggested to read "Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Ethical Considerations in the Conduct and Reporting of Research: Conflicts of Interest" from International Committee of Medical Journal Editors (ICMJE), which is available at: http://www.icmje.org/ethical_4conflicts.html.

Sample wording: [Name of individual] has received fees for serving as a speaker, a consultant and an advisory board member for [names of organizations], and has received research funding from [names of organization]. [Name of individual] is an employee of [name of organization]. [Name of individual] owns stocks and shares in [name of organization]. [Name of individual] owns patent [patent identification and brief description].

Statement of informed consent

Manuscripts should contain a statement to the effect that all human studies have been reviewed by the appropriate ethics committee or it should be stated clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under study should be omitted. Authors should also draw attention to the Code of Ethics of the World Medical Association (Declaration of Helsinki, 1964, as revised in 2004).

Statement of human and animal rights

When reporting the results from experiments, authors should follow the highest standards and the trial should conform to Good Clinical Practice (for example, US Food and Drug Administration Good Clinical Practice in FDA-Regulated Clinical Trials; UK Medicines Research Council Guidelines for Good Clinical Practice in Clinical Trials) and/or the World Medical Association Declaration of Helsinki. Generally, we suggest authors follow the lead investigator's national standard. If doubt exists whether the research was conducted in accordance with the above standards, the authors must explain the rationale for their approach and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study.

Before submitting, authors should make their study approved by the relevant research ethics committee or institutional review board. If human participants were involved, manuscripts must be accompanied by a statement that the experiments were undertaken with the understanding and appropriate informed consent of each. Any personal item or information will not be published without explicit consents from the involved patients. If experimental animals were used, the materials and methods (experimental procedures) section must clearly indicate that appropriate measures were taken

to minimize pain or discomfort, and details of animal care should be provided.

SUBMISSION OF MANUSCRIPTS

Manuscripts should be typed in 1.5 line spacing and 12 pt. Book Antiqua with ample margins. Number all pages consecutively, and start each of the following sections on a new page: Title Page, Abstract, Introduction, Materials and Methods, Results, Discussion, Acknowledgements, References, Tables, Figures, and Figure Legends. Neither the editors nor the publisher are responsible for the opinions expressed by contributors. Manuscripts formally accepted for publication become the permanent property of Baishideng Publishing Group Co., Limited, and may not be reproduced by any means, in whole or in part, without the written permission of both the authors and the publisher. We reserve the right to copy-edit and put onto our website accepted manuscripts. Authors should follow the relevant guidelines for the care and use of laboratory animals of their institution or national animal welfare committee. For the sake of transparency in regard to the performance and reporting of clinical trials, we endorse the policy of the ICMJE to refuse to publish papers on clinical trial results if the trial was not recorded in a publicly-accessible registry at its outset. The only register now available, to our knowledge, is <http://www.clinicaltrials.gov> sponsored by the United States National Library of Medicine and we encourage all potential contributors to register with it. However, in the case that other registers become available you will be duly notified. A letter of recommendation from each author's organization should be provided with the contributed article to ensure the privacy and security of research is protected.

Authors should retain one copy of the text, tables, photographs and illustrations because rejected manuscripts will not be returned to the author(s) and the editors will not be responsible for loss or damage to photographs and illustrations sustained during mailing.

Online submissions

Manuscripts should be submitted through the Online Submission System at: <http://www.wjgnet.com/1948-0210/office>. Authors are highly recommended to consult the ONLINE INSTRUCTIONS TO AUTHORS (http://www.wjgnet.com/1948-0210/g_info_20100313165700.htm) before attempting to submit online. For assistance, authors encountering problems with the Online Submission System may send an email describing the problem to wjsc@wjgnet.com, or by telephone: +86-10-85381891. If you submit your manuscript online, do not make a postal contribution. Repeated online submission for the same manuscript is strictly prohibited.

MANUSCRIPT PREPARATION

All contributions should be written in English. All articles must be submitted using word-processing software. All submissions must be typed in 1.5 line spacing and 12 pt. Book Antiqua with ample margins. Style should conform to our house format. Required information for each of the manuscript sections is as follows:

Title page

Title: Title should be less than 12 words.

Running title: A short running title of less than 6 words should be provided.

Authorship: Authorship credit should be in accordance with the standard proposed by International Committee of Medical Journal Editors, based on (1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; (2) drafting the article or revising it critically for important intellectual content; and (3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3.

Institution: Author names should be given first, then the complete name of institution, city, province and postcode. For example, Xu-

Chen Zhang, Li-Xin Mei, Department of Pathology, Chengde Medical College, Chengde 067000, Hebei Province, China. One author may be represented from two institutions, for example, George Sgourakis, Department of General, Visceral, and Transplantation Surgery, Essen 45122, Germany; George Sgourakis, 2nd Surgical Department, Korgialenio-Benakio Red Cross Hospital, Athens 15451, Greece

Author contributions: The format of this section should be: Author contributions: Wang CL and Liang L contributed equally to this work; Wang CL, Liang L, Fu JF, Zou CC, Hong F and Wu XM designed the research; Wang CL, Zou CC, Hong F and Wu XM performed the research; Xue JZ and Lu JR contributed new reagents/analytic tools; Wang CL, Liang L and Fu JF analyzed the data; and Wang CL, Liang L and Fu JF wrote the paper.

Supportive foundations: The complete name and number of supportive foundations should be provided, e.g. Supported by National Natural Science Foundation of China, No. 30224801

Correspondence to: Only one corresponding address should be provided. Author names should be given first, then author title, affiliation, the complete name of institution, city, postcode, province, country, and email. All the letters in the email should be in lower case. A space interval should be inserted between country name and email address. For example, Montgomery Bissell, MD, Professor of Medicine, Chief, Liver Center, Gastroenterology Division, University of California, Box 0538, San Francisco, CA 94143, United States. montgomery.bissell@ucsf.edu

Telephone and fax: Telephone and fax should consist of +, country number, district number and telephone or fax number, e.g. Telephone: +86-10-85381891 Fax: +86-10-85381893

Peer reviewers: All articles received are subject to peer review. Normally, three experts are invited for each article. Decision for acceptance is made only when at least two experts recommend an article for publication. Reviewers for accepted manuscripts are acknowledged in each manuscript, and reviewers of articles which were not accepted will be acknowledged at the end of each issue. To ensure the quality of the articles published in *WJSC*, reviewers of accepted manuscripts will be announced by publishing the name, title/position and institution of the reviewer in the footnote accompanying the printed article. For example, reviewers: Professor Jing-Yuan Fang, Shanghai Institute of Digestive Disease, Shanghai, Affiliated Renji Hospital, Medical Faculty, Shanghai Jiaotong University, Shanghai, China; Professor Xin-Wei Han, Department of Radiology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan Province, China; and Professor Anren Kuang, Department of Nuclear Medicine, Huaxi Hospital, Sichuan University, Chengdu, Sichuan Province, China.

Abstract

There are unstructured abstracts (no more than 256 words) and structured abstracts (no more than 480). The specific requirements for structured abstracts are as follows:

An informative, structured abstracts of no more than 480 words should accompany each manuscript. Abstracts for original contributions should be structured into the following sections. AIM (no more than 20 words): Only the purpose should be included. Please write the aim as the form of "To investigate/study/...; MATERIALS AND METHODS (no more than 140 words); RESULTS (no more than 294 words): You should present *P* values where appropriate and must provide relevant data to illustrate how they were obtained, e.g. 6.92 ± 3.86 vs 3.61 ± 1.67 , $P < 0.001$; CONCLUSION (no more than 26 words).

Key words

Please list 5-10 key words, selected mainly from *Index Medicus*, which reflect the content of the study.

Text

For articles of these sections, original articles and brief articles, the main text should be structured into the following sections: INTRODUCTION, MATERIALS AND METHODS, RESULTS and DISCUSSION, and should include appropriate Figures and Tables. Data should be presented in the main text or in Figures and Tables, but not in both. The main text format of these sections, editorial, topic highlight, case report, letters to the editors, can be found at: http://www.wjgnet.com/1948-0210/g_info_list.htm.

Illustrations

Figures should be numbered as 1, 2, 3, *etc.*, and mentioned clearly in the main text. Provide a brief title for each figure on a separate page. Detailed legends should not be provided under the figures. This part should be added into the text where the figures are applicable. Figures should be either Photoshop or Illustrator files (in tiff, eps, jpeg formats) at high-resolution. Examples can be found at: <http://www.wjgnet.com/1007-9327/13/4520.pdf>; <http://www.wjgnet.com/1007-9327/13/4554.pdf>; <http://www.wjgnet.com/1007-9327/13/4891.pdf>; <http://www.wjgnet.com/1007-9327/13/4986.pdf>; <http://www.wjgnet.com/1007-9327/13/4498.pdf>. Keeping all elements compiled is necessary in line-art image. Scale bars should be used rather than magnification factors, with the length of the bar defined in the legend rather than on the bar itself. File names should identify the figure and panel. Avoid layering type directly over shaded or textured areas. Please use uniform legends for the same subjects. For example: Figure 1 Pathological changes in atrophic gastritis after treatment. A: ...; B: ...; C: ...; D: ...; E: ...; F: ...; G: ...*etc.* It is our principle to publish high resolution-figures for the printed and E-versions.

Tables

Three-line tables should be numbered 1, 2, 3, *etc.*, and mentioned clearly in the main text. Provide a brief title for each table. Detailed legends should not be included under tables, but rather added into the text where applicable. The information should complement, but not duplicate the text. Use one horizontal line under the title, a second under column heads, and a third below the Table, above any footnotes. Vertical and italic lines should be omitted.

Notes in tables and illustrations

Data that are not statistically significant should not be noted. ^a*P* < 0.05, ^b*P* < 0.01 should be noted (*P* > 0.05 should not be noted). If there are other series of *P* values, ^c*P* < 0.05 and ^d*P* < 0.01 are used. A third series of *P* values can be expressed as ^e*P* < 0.05 and ^f*P* < 0.01. Other notes in tables or under illustrations should be expressed as ¹F, ²F, ³F; or sometimes as other symbols with a superscript (Arabic numerals) in the upper left corner. In a multi-curve illustration, each curve should be labeled with ●, ○, ■, □, ▲, △, *etc.*, in a certain sequence.

Acknowledgments

Brief acknowledgments of persons who have made genuine contributions to the manuscript and who endorse the data and conclusions should be included. Authors are responsible for obtaining written permission to use any copyrighted text and/or illustrations.

REFERENCES

Coding system

The author should number the references in Arabic numerals according to the citation order in the text. Put reference numbers in square brackets in superscript at the end of citation content or after the cited author's name. For citation content which is part of the narration, the coding number and square brackets should be typeset normally. For example, "Crohn's disease (CD) is associated with increased intestinal permeability^[1,2]". If references are cited directly in the text, they should be put together within the text, for example, "From references^[19,22-24], we know that..."

When the authors write the references, please ensure that the order in text is the same as in the references section, and also

Instructions to authors

ensure the spelling accuracy of the first author's name. Do not list the same citation twice.

PMID and DOI

Please provide PubMed citation numbers to the reference list, e.g. PMID and DOI, which can be found at <http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed> and <http://www.crossref.org/SimpleTextQuery/>, respectively. The numbers will be used in E-version of this journal.

Style for journal references

Authors: the name of the first author should be typed in bold-faced letters. The family name of all authors should be typed with the initial letter capitalized, followed by their abbreviated first and middle initials. (For example, Lian-Sheng Ma is abbreviated as Ma LS, Bo-Rong Pan as Pan BR). The title of the cited article and italicized journal title (journal title should be in its abbreviated form as shown in PubMed), publication date, volume number (in black), start page, and end page [PMID: 11819634 DOI: 10.3748/wjg.13.5396].

Style for book references

Authors: the name of the first author should be typed in bold-faced letters. The surname of all authors should be typed with the initial letter capitalized, followed by their abbreviated middle and first initials. (For example, Lian-Sheng Ma is abbreviated as Ma LS, Bo-Rong Pan as Pan BR) Book title. Publication number. Publication place: Publication press, Year: start page and end page.

Format

Journals

English journal article (list all authors and include the PMID where applicable)

- 1 **Jung EM**, Clevert DA, Schreyer AG, Schmitt S, Rennert J, Kubale R, Feuerbach S, Jung F. Evaluation of quantitative contrast harmonic imaging to assess malignancy of liver tumors: A prospective controlled two-center study. *World J Gastroenterol* 2007; **13**: 6356-6364 [PMID: 18081224 DOI: 10.3748/wjg.13.6356]

Chinese journal article (list all authors and include the PMID where applicable)

- 2 **Lin GZ**, Wang XZ, Wang P, Lin J, Yang FD. Immunologic effect of Jianpi Yishen decoction in treatment of Pixu-diarhoea. *Shijie Huaren Xiaobua Zazhi* 1999; **7**: 285-287

In press

- 3 **Tian D**, Araki H, Stahl E, Bergelson J, Kreitman M. Signature of balancing selection in Arabidopsis. *Proc Natl Acad Sci USA* 2006; In press

Organization as author

- 4 **Diabetes Prevention Program Research Group**. Hypertension, insulin, and proinsulin in participants with impaired glucose tolerance. *Hypertension* 2002; **40**: 679-686 [PMID: 12411462 PMCID:2516377 DOI:10.1161/01.HYP.0000035706.28494.09]

Both personal authors and an organization as author

- 5 **Vallancien G**, Emberton M, Harving N, van Moorselaar RJ; Alf-One Study Group. Sexual dysfunction in 1, 274 European men suffering from lower urinary tract symptoms. *J Urol* 2003; **169**: 2257-2261 [PMID: 12771764 DOI:10.1097/01.ju.0000067940.76090.73]

No author given

- 6 21st century heart solution may have a sting in the tail. *BMJ* 2002; **325**: 184 [PMID: 12142303 DOI:10.1136/bmj.325.7357.184]

Volume with supplement

- 7 **Geraud G**, Spierings EL, Keywood C. Tolerability and safety of frovatriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan. *Headache* 2002; **42** Suppl 2: S93-99 [PMID: 12028325 DOI:10.1046/j.1526-4610.42.s2.7.x]

Issue with no volume

- 8 **Banit DM**, Kaufer H, Hartford JM. Intraoperative frozen section analysis in revision total joint arthroplasty. *Clin Orthop Relat Res* 2002; (**401**): 230-238 [PMID: 12151900 DOI:10.1097/00003086-200208000-00026]

No volume or issue

- 9 Outreach: Bringing HIV-positive individuals into care. *HRSA Careaction* 2002; 1-6 [PMID: 12154804]

Books

Personal author(s)

- 10 **Sherlock S**, Dooley J. Diseases of the liver and biliary system. 9th ed. Oxford: Blackwell Sci Pub, 1993: 258-296

Chapter in a book (list all authors)

- 11 **Lam SK**. Academic investigator's perspectives of medical treatment for peptic ulcer. In: Swabb EA, Azabo S. Ulcer disease: investigation and basis for therapy. New York: Marcel Dekker, 1991: 431-450

Author(s) and editor(s)

- 12 **Breedlove GK**, Schorfheide AM. Adolescent pregnancy. 2nd ed. Wiczorek RR, editor. White Plains (NY): March of Dimes Education Services, 2001: 20-34

Conference proceedings

- 13 **Harnden P**, Joffe JK, Jones WG, editors. Germ cell tumours V. Proceedings of the 5th Germ cell tumours Conference; 2001 Sep 13-15; Leeds, UK. New York: Springer, 2002: 30-56

Conference paper

- 14 **Christensen S**, Oppacher F. An analysis of Koza's computational effort statistic for genetic programming. In: Foster JA, Lutton E, Miller J, Ryan C, Tettamanzi AG, editors. Genetic programming. EuroGP 2002: Proceedings of the 5th European Conference on Genetic Programming; 2002 Apr 3-5; Kinsdale, Ireland. Berlin: Springer, 2002: 182-191

Electronic journal (list all authors)

- 15 Morse SS. Factors in the emergence of infectious diseases. *Emerg Infect Dis* serial online, 1995-01-03, cited 1996-06-05; 1(1): 24 screens. Available from: URL: <http://www.cdc.gov/ncidod/eid/index.htm>

Patent (list all authors)

- 16 **Pagedas AC**, inventor; Ancel Surgical R&D Inc., assignee. Flexible endoscopic grasping and cutting device and positioning tool assembly. United States patent US 20020103498. 2002 Aug 1

Statistical data

Write as mean \pm SD or mean \pm SE.

Statistical expression

Express *t* test as *t* (in italics), *F* test as *F* (in italics), chi square test as χ^2 (in Greek), related coefficient as *r* (in italics), degree of freedom as ν (in Greek), sample number as *n* (in italics), and probability as *P* (in italics).

Units

Use SI units. For example: body mass, *m* (B) = 78 kg; blood pressure, *p* (B) = 16.2/12.3 kPa; incubation time, *t* (incubation) = 96 h, blood glucose concentration, *c* (glucose) 6.4 ± 2.1 mmol/L; blood CEA mass concentration, *p* (CEA) = 8.6 ± 24.5 μ g/L; CO₂ volume fraction, 50 mL/L CO₂, not 5% CO₂; likewise for 40 g/L formaldehyde, not 10% formalin; and mass fraction, 8 ng/g, etc. Arabic numerals such as 23, 243, 641 should be read 23 243 641.

The format for how to accurately write common units and quantum numbers can be found at: http://www.wjgnet.com/1948-0210/g_info_20100313172144.htm.

Abbreviations

Standard abbreviations should be defined in the abstract and on first mention in the text. In general, terms should not be abbreviated unless they are used repeatedly and the abbreviation is helpful to the reader. Permissible abbreviations are listed in Units, Symbols and Abbreviations: A Guide for Biological and Medical Editors and

Authors (Ed. Baron DN, 1988) published by The Royal Society of Medicine, London. Certain commonly used abbreviations, such as DNA, RNA, HIV, LD50, PCR, HBV, ECG, WBC, RBC, CT, ESR, CSF, IgG, ELISA, PBS, ATP, EDTA, mAb, can be used directly without further explanation.

Italics

Quantities: *t* time or temperature, *c* concentration, *A* area, *l* length, *m* mass, *V* volume.

Genotypes: *gyrA*, *arg 1*, *c myc*, *c fos*, etc.

Restriction enzymes: *EcoRI*, *HindII*, *BamHI*, *Kbo I*, *Kpn I*, etc.

Biology: *H. pylori*, *E. coli*, etc.

Examples for paper writing

Editorial: http://www.wjgnet.com/1948-0210/g_info_20100313165833.htm

Frontier: http://www.wjgnet.com/1948-0210/g_info_20100313170509.htm

Topic highlight: http://www.wjgnet.com/1948-0210/g_info_20100313170618.htm

Observation: http://www.wjgnet.com/1948-0210/g_info_20100313170727.htm

Guidelines for basic research: http://www.wjgnet.com/1948-0210/g_info_20100313170855.htm

Guidelines for clinical practice: http://www.wjgnet.com/1948-0210/g_info_20100313171012.htm

Review: http://www.wjgnet.com/1948-0210/g_info_20100313171124.htm

Original articles: http://www.wjgnet.com/1948-0210/g_info_20100313171239.htm

Brief articles: http://www.wjgnet.com/1948-0210/g_info_20100313171358.htm

Case report: http://www.wjgnet.com/1948-0210/g_info_20100313171504.htm

Letters to the editor: http://www.wjgnet.com/1948-0210/g_info_20100313171613.htm

Book reviews: http://www.wjgnet.com/1948-0210/g_info_20100313171713.htm

Guidelines: http://www.wjgnet.com/1948-0210/g_info_20100313171803.htm

SUBMISSION OF THE REVISED MANUSCRIPTS AFTER ACCEPTED

Please revise your article according to the revision policies of *WJSC*. The revised version including manuscript and high-resolution image figures (if any) should be copied on a floppy or compact disk. The author should send the revised manuscript, along with printed high-resolution color or black and white photos,

copyright transfer letter, and responses to the reviewers by courier (such as EMS/DHL).

Editorial Office

World Journal of Stem Cells

Editorial Department: Room 903, Building D, Ocean International Center, No. 62 Dongsihuan Zhonglu, Chaoyang District, Beijing 100025, China

E-mail: wjsc@wjgnet.com

<http://www.wjgnet.com>

Telephone: +86-10-8538-1891

Fax: +86-10-8538-1893

Language evaluation

The language of a manuscript will be graded before it is sent for revision. (1) Grade A: priority publishing; (2) Grade B: minor language polishing; (3) Grade C: a great deal of language polishing needed; and (4) Grade D: rejected. Revised articles should reach Grade A or B.

Copyright assignment form

Please download a Copyright assignment form from http://www.wjgnet.com/1948-0210/g_info_20100313172045.htm.

Responses to reviewers

Please revise your article according to the comments/suggestions provided by the reviewers. The format for responses to the reviewers' comments can be found at: http://www.wjgnet.com/1948-0210/g_info_20100313172000.htm.

Proof of financial support

For paper supported by a foundation, authors should provide a copy of the document and serial number of the foundation.

Links to documents related to the manuscript

WJSC will be initiating a platform to promote dynamic interactions between the editors, peer reviewers, readers and authors. After a manuscript is published online, links to the PDF version of the submitted manuscript, the peer-reviewers' report and the revised manuscript will be put on-line. Readers can make comments on the peer reviewer's report, authors' responses to peer reviewers, and the revised manuscript. We hope that authors will benefit from this feedback and be able to revise the manuscript accordingly in a timely manner.

Science news releases

Authors of accepted manuscripts are suggested to write a science news item to promote their articles. The news will be released rapidly at EurekAlert/AAAS (<http://www.eurekalert.org>). The title for news items should be less than 90 characters; the summary should be less than 75 words; and main body less than 500 words. Science news items should be lawful, ethical, and strictly based on your original content with an attractive title and interesting pictures.

Publication fee

WJSC is an international, peer-reviewed, Open-Access, online journal. Articles published by this journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. Authors of accepted articles must pay a publication fee. The related standards are as follows. Publication fee: 1300 USD per article. Editorial, topic highlights, book reviews and letters to the editor are published free of charge.